



JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of
MAY Campilas, et al

Examiner: Not Assigned

Art Unit: 1614

Application No.: 10/727,911

Filed: December 4, 2003

Title: **Novel Heterocyclic Compounds, Their
Preparation and Their Use as
Medicaments, in Particular as
Antibacterials and Beta-Lactamase
Inhibitors**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450, on

September 16, 2004

Date of Deposit

Bonnie Stein
Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.


A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

A copy of the French Search Report is enclosed for your convenience.

U.S. Patent 5,932,587 is the English language equivalent to EP 0 818 197 A1.
A copy of the English Abstract is attached to: Fr. 2,676,230.

Based on the new USPTO procedures, it is not required to submit copies of U.S. patents and U.S. publications for all applications filed after June 30, 2003. Therefore, a copy of the one (1) reference is not enclosed with this Information Disclosure Statement.

Respectfully submitted,



Irving Newman, Reg. No. 22,638
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626
Aventis Docket No. FRAV2002/0034US NP

☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SEP 20 2004
O.I.P.E.
PATENT & TRADEMARK OFFICE

Complete if Known

Application Number	10/727,911
Filing Date	12-04-2003
First Named Inventor	ROWLANDS
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	FRAV2002/0034 - US - NP

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/727,911	
			Filing Date	12-04-2003	
			First Named Inventor	ROWLANDS	
			Group Art Unit		
			Examiner Name	1614	
Sheet	2	of	2	Attorney Docket Number	FRAV2002/0034 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHEN et al, Synthesis of N-substituted 1,6-Dihydro-3(2H)-Pyridinones and 1-Acyl-3-Piperidones, Heterocycles, Vol. 22, No. 12, 1984, pp 2769-2773	
		HALL, Jr. et al, 3-Isopropyl-1,3-diazabicyclo[3.3.1]nonan-2-one, a Simple Bicyclic Urea with a Bridgehead Nitrogen Atom, J. Org. Chem., Vol. 37, Issue 5, 1972, pp 697-699	
		HALL, Jr. et al, Anti-Bredt Bridgehead Nitrogen Compounds in Ring-Opening Polymerization, Chemical Reviews, Vol. 83, Issue 5, 1983, pp 549-555	
		HALL, Jr. et al, Anti-Bredt Molecules. 3.1a 3-Oxa-1-azabicyclo[3.3.1]nonan-2-one and 6-Oxa-1-azabicyclo[3.2.1]octan-7-one, two Atome-Bridged Bicyclic Urethanes Possessing Bridgehead Nitrogen, J. Org. Chem., Vol. 45, Issue 26, 1980, pp 5325-5326	
		ITOH, Synthesis and Structure of 4-Substituted Decahydroisoquinoline Derivatives, Chem. Pharm. Bull., Vol. 16, Issue 3, 1968, pp 455-470	
		NICOLAOU et al, New Synthetic Technology for the Rapid Construction of Novel Heterocycles - Part 2. The Reaction of IBX with Anilides and Related Compounds, Chem. Int. Ed. 2000, Vol. 39, Issue 3, 2000, pp625-628	
		PENNINGTON et al, Preparation and cyclization of substituted 1-anilino-3-halo-2- propanols and their conversion to indoles, Chem. Abs. RN 3189-20-6 and Journal of Organic Chemistry, Vol. 30, No. 8, 1965, pp 2801-1804	
		SHIOTANI et al, Studies on Diazabenzobicyclo[3.3.1]nonane System. M+1 Syntheses of 1,2,3,4-Tetrahydro-6H-1,5-methanobenzo[d][1,2] diazocine Derivatives, Chemical Pharm. Bull., Vol. 15, Issue 1, 1967, pp 88-93	
		TRIEBS et al, Experiments for the preparation of azatropolones. I. Disubstituted 1-aza-4,5-cycloheptanedione and 5-azatropolone, Chem. Abs. RN 106478-62-0 and Journal Fuer Praktische Chemie (LEIPZIG), Vol. 14, 1961, pp 208-217	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.